David A. Siegel Altimmune, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Altimmune, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 69,400 shares of ALT stock, worth $510,090. This represents 0.0% of its overall portfolio holdings.

Number of Shares

69,400

Holding current value

$510,090

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.91 - $10.23 $410,154 - $709,962	69,400 New	69,400 $461,000
Q3 2023 Nov 14, 2023	SELL	$2.4 - $3.45 $49,920 - $71,760	-20,800 Reduced 2.17%	937,000 $2.44 Million
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $22,425 - $38,805	6,500 Added 0.68%	957,800 $3.38 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $108,940 - $437,579	26,000 Added 2.81%	951,300 $4.01 Million
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $493,810 - $929,425	56,500 Added 6.5%	925,300 $15.2 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $1.09 Million - $2.29 Million	102,200 Added 13.33%	868,800 $11.1 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $298,652 - $892,166	75,800 Added 10.97%	766,600 $8.97 Million
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $788,240 - $1.26 Million	133,600 Added 23.98%	690,800 $4.21 Million
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $4.84 Million - $6.95 Million	557,200 New	557,200 $5.1 Million
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $2.33 Million - $3.89 Million	-236,200 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$12.71 - $24.31 $1.38 Million - $2.64 Million	-108,400 Reduced 31.46%	236,200 $3.34 Million
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $1.15 Million - $2.09 Million	-147,300 Reduced 29.95%	344,600 $3.89 Million
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $4.88 Million - $16.4 Million	491,900 New	491,900 $6.49 Million

Others Institutions Holding ALT

# of Institutions

190

Shares Held

42M

Call Options Held

1.05M

Put Options Held

582K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $360M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account